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TKI constitute a new group of drugs evaluated in TC
patients. The efficacy of some of them in prolongation of
progression free survival has been recently documented.
However, possible side effects may affect the quality of life
as well as limit their clinical use. Only drugs which were
known to inhibit VEGFR were considered. In the study
adverse effects were evaluated in patients treated in our
centre within the prospective clinical trials phase II and
III. The aim of the study was to analyze the frequency and
severity of side effects related to TKI in TC patients. Thus,
we retrospectively re-evaluated side effects on the basis of
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. The comparison of the drugs was
not aimed.
37 therapies with TKI due to advanced TC were
assessed. 19 subjects were given vandetanib, 15 - lenvatinib,
3 - axitinib. Median treatment duration was 26.7 months
(range: 4.0 - 62.2). The drug was discontinued due to TC
progression in 9 subjects, adverse events in 5 and for other
reasons in 4. Adverse events leading to treatment withdra-
wal were: weight loss (1), lymphopenia (1), QTC prolon-
gation (1), tracheo-esophageal fistula (1) and purulent
meningitis (1).
The results are given in table 1.
Conclusions
Tolerability and safety of the treatment with tyrosine
kinase inhibitors in advanced TC patients was acceptable
(most adverse reactions G1-G2). Only in 13.5% cases
treatment discontinuation was required.
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Table 1 Frequency and severity of the most common
treatment-related side effects.
G1 / G2 / G3 Total Treatable Dose reduction
Skin reactions 16 / 8 / 2 26 (70.3%) yes no
Arterial
hypertension
3 / 7 / 17 27 (73.0%) yes 1
Diarrhea 7 / 9 / 4 20 (54.1%) yes 4
Weight loss 4 / 13 / 3 20 (54.1%) yes 5
Stomatitis 15 /1 / - 16 (43.2%) yes no
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